Diffuse Large B-cell Lymphoma (DLBCL) is the most common lymphoma in adults. Even though cure rates have significantly improved in the last few years since the introduction of new immunochemotherapy treatments, refractory/relapse cases reach up to 40%. DLBCL is a highly heterogeneous disease and new biomarkers are highly awaited for better DLBCL stratification, prognosis and tailored therapies. We have shown that the transcription factor RelB is frequently activated in a large cohort of DLBCL patients and cell lines independently of their known subtypes, and that RelB activity defines a new subset of DLBCL patients with a peculiar gene expression profile and mutational pattern. Additionally, the newly defined RelB-positive subgroup exhibits a dismal outcome following immunochemotherapy. This new RelB signature then contributes to better DLBCL patient’s stratification and prognosis and paves the way toward new therapeutic approaches based on RelB activation status.
Keywords: Diffuse large B-cell lymphoma (DLBCL), RelB, NF-ĸB signaling, Prognosis, Biomarker, Patient stratification, Transcription factor